Study of Apoptosis Induced by 188Re-DTPA-DG in MCF-7 Breast Carcinoma and A549 Pulmonary Carcinoma Cells

Preliminary Studies of 177Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice

Objective: The purpose of this study was to explore the potential use of ¹⁷⁷Lu-diethylenetriamine penta-acetic acid-deoxyglucose (¹⁷⁷Lu-DTPA-DG) as a radiopharmaceutical for hepatic tumor treatment. Methods: Lutetium-177 (¹⁷⁷Lu) was labeled with DTPA-DG by adding 2 mCi ¹⁷⁷LuCl₃ to 0.05 mg DTPA-DG (pH 5-6) at room temperature for 1 h. The quality of the¹⁷⁷Lu-DTPA-DG solutions was determined by thin-layer chromatography and high-performance liquid chromatography. Cellular uptake studies with ¹⁸F-fluorodeoxyglucose (FDG), ¹⁷⁷Lu-DTPA-DG and ¹⁷⁷Lu-DTPA and a blocking study with 1.0 mg d-glucose were performed. Biodistribution, imaging, and radiotherapy studies of ¹⁷⁷Lu-DTPA-DG were performed with the SMMC-7721 model. Results: ¹⁷⁷Lu-DTPA-DG had a high radiochemical purity (>97%). The cellular uptake of ¹⁷⁷Lu-DTPA-DG was much higher than that of the ¹⁷⁷Lu-DTPA. The biodistribution of ¹⁷⁷Lu-DTPA-DG demonstrated that the complex accumulated in the tumor with high tumor/blood and tumor/muscle ratios. The tumors in mice in the ¹⁷⁷Lu-DTPA-DG group clearly displayed the high uptake of ¹⁷⁷Lu-DTPA-DG. After radiotherapy with ¹⁷⁷Lu-DTPA-DG, tumor growth decreased, and the overall survival was longer than that in the ¹⁷⁷LuCl₃ group (268.58 ± 17.96 mm³ vs. 507.43 ± 55.72 mm³, p = 0.002) and the normal saline group (268.58 ± 17.96 mm³ vs. 483.68 ± 27.51 mm³, p < 0.05). Conclusions: This preliminary study suggests that ¹⁷⁷Lu-DTPA-DG has the potential to become a liver radiopharmaceutical agent and should be further investigated.

In vitro evaluation of apoptosis with 99mTc-glucoheptonate

Radiopharmaceuticals are useful to evaluate effectiveness of cancer treatments as well as diagnosis of diseases. (99m)Tc-Glucoheptonate has high sensitivity for imaging lung cancer tissues. In this study, the potential use of (99m)Tc-glucoheptonate for monitoring apoptosis related to chemotherapeutic agents is investigated in vitro using A549 lung cancer cell line. A decrease in (99m)Tc-glucoheptonate uptake ratio was observed depending on the level of apoptosis. (99m)Tc-glucoheptonate is found to be useful for the detection of apoptosis following treatment in A549 lung tumor cells.

Review: Deoxyglucose compounds labeled with isotopes different from 18-fuoride: is there a future in clinical practice?

There are several radionuclide-labeled derivatives of deoxyglucose (DG) that have been developed including 2-fluro-deoxyglucose, ethylenedicysteine-deoxyglucose, diethylenetriaminepentaacetate-deoxyglucose, N-(2'-hydroxybenzyl)-2-amino-2-deoxy-D-glucose, and methyl D-glucoside that were synthesized and successfully labeled in high labeling fields. The former 4 were used for tumor imaging and methyl-D-glucoside for the diagnosis and the monitoring of the functional status of renal tubules. These derivatives are suitable for imaging examinations when labeled with either fluorine-18 (18F), technetium-99m (99mTc), carbon-11 (11C), or gallium-68 (68Ga). These compounds are suitable both for imaging and for therapy if labeled with rhenium-188 (188Re). In the area of molecular imaging of nuclear medicine, derivatives of radionuclide-labeled deoxyglucose will become an important tool for the diagnosis and carcinoma treatment in the clinic.